Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes

Review covers evaluation of CV risk, glycaemic targets, modification of lifestyle and CV risk factors, and glucose-lowering medications (insulin, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors).

Source:

New England Journal of Medicine